Sponsor Pipeline

QED Therapeutics, a BridgeBio company Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
5
Active Trials
2
Recruiting
1
Phase 3
Active Trials by Phase
Phase 2/3
1
Phase 2
3
Not specified
1
Active Trials
NCT IDTitleConditionStatus
Phase 2/3
NCT06873035 An Interventional Study of Infigratinib in Children With Hypochondroplasia Hypochondroplasia Enrolling by Invitation
Phase 2
NCT07169279 Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH) Achondroplasia Recruiting
NCT05145010 Extension Study of Infigratinib in Children With Achondroplasia (ACH) Achondroplasia Enrolling by Invitation
NCT07393373 Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia Hypochondroplasia Enrolling by Invitation
Not specified
NCT06410976 Prospective Clinical Assessment Study in Children With Hypochondroplasia Hypochondroplasia Recruiting
Get alerts when QED Therapeutics, a BridgeBio company's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free